INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network
17 May 2024 - Elementos Limited (ASX:ELT) Managing Director Joe David discusses the recommencement of DFS and licensing activities following discussions with the Andalusian government.
Read More21 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
Read More29 Nov 2019 - Xplore Wealth Limited (ASX:XPL) CEO, Michael Wright, talks about the benefits of the company's non-aligned platform following the Hayne Royal Commission and key priorities for FY20.
Read More30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
Read More20 Mar 2023 - Beston Global Food Company Limited (ASX:BFC) CEO Fabrizio Jorge discusses half-year results, the impact of weather on milk supply, lactoferrin pricing, export markets, the recent capital raising, and M&A opportunities.
Read More24 Nov 2020 - Altech Chemicals Limited (ASX:ATC) Managing Director Iggy Tan provides an update on construction of the company's high purity alumina (HPA) processing plant in Malaysia, its funding plans for the next phase of construction, growing HPA applications and plans for a second HPA plant in Saxony, Germany.
Read More11 Apr 2023 - Altech Batteries Limited (ASX:ATC) CFO Martin Stein discusses the company's GridPack batteries for the renewable energy storage market and progress with the CERENERGY project.
Read More16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
Read More11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
Read More20 Nov 2019 - Ausbil Investment Management Chief Investment Officer, Paul Xiradis and Ausbil Head of ESG Research, Måns Carlsson-Sweeny, provide an update on the Ausbil Active Sustainable Equity fund’s performance, talk about what the fund looks for in businesses that fit the description of "sustainable", and discuss how these characteristics provide long-term above-market returns.
Read More
